ArticleJTO clinical and research reports2025

Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 Driven Resistance in a Patient With NSCLC After Osimertinib Progression: Case Report.

Hailey M Hirata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.